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Summary
1. Objective: Develop new Lanthanide (III) glycoconjugate chelates of 
DPTA capable of targeting the liver asialoglycoprotein receptor 
(ASGPR) - lectin with physico-chemical and biological properties 
capable of making them potential agents for liver imaging
2.   Synthesis and physico-chemical characterization of dendrimeric
DTPA based glycoconjugate ligands
3. Physico-chemical characterization of their Ln(III) chelates: 
- NMR study of the Eu(III) and Sm(III) chelates
- Relaxivity (NMRD) study of the Gd(III) chelates and their lectin 
binding; determination of molecular parameters
Active targeting for medical diagnostic
Cell surface receptor
(internalization –
Intracellular delivery)
linker
Vector molecule
(peptide, antibody, 
carbohydrate,...)
Bifunctional 
chelator
Paramagnetic (Gd(III)) : MRI
Metal ion 
Gamma emitter: scintigraphy
Lectins : non-enzymatic proteins or glycoproteins which bind to carbohydrates 
and act as recognition determinants in many biological processes
Targeting Lectins
- ASGP-R recognizes terminal β-galactosyl residues on desialylated
glycoproteins
- Control of intracellular traffic of glycoproteins and liver clearance from  the 
circulatory system of desialylated glycoproteins and apoptotic cells 
- Interactions of tumour cells with the immune system, masked by sialyl
terminals
- Adhesion of infectious agents to host cells
- Recruitment of leucocytes to inflammatory sites (Selectins) 
Molecular fit between pairs of complementary structures:
lectins    Ù carbohydrates (ligands)
This action can be blocked by appropriate sugars  in vivo and in vitro
Liver ASGP Receptor
Structural aspects
-Composed of two homologous subunits, smaller H1 and bigger H2 in humans (ratio
3:1).
-Each subunit is a type II transmembrane lectin specific to Gal/N-AcGal.
-Each subunit  has a short aa cytoplasmatic N terminus, a hydrophobic membrane 
domain, and an exoplasmatic carboxy terminus exhibiting a carbohydrate 
recognition domain (CRD) which requires Ca2+ ions.
Models of subunit organization of rat 
ASGP-R (RHL)
Organization of membrane bound C-type lectins
Mannose macrophage
receptor
Chicken hepatic
lectin
Kupffer cell 
receptor L-selectin
Crystal Structure of CRD of H1 Subunit of ASGP-R
Ca(2) binding site (8 O atoms)
Gal binds at Ca(2) binding site
replaces axial water molecules 
11 and 13 by (3)OH and (4)OH 
groups of the carbohydrate 
Overlay of sugar binding site of H1-CRD of ASGPR 
and CDR of MBP mutant  containing N-AcGal
Structure of H1- CRD (aas 147-290)
Burkhard,…J Mol Biol, 2000
Liver ASGP Receptor
Receptor mediated endocytosis via chlathrin-coated pit pathway
Ligands are cleared from 
the circulation by receptor-
mediated endocytosis and 
degraded in lysosomes, 
while the receptor is 
recycled to the cell surface.
1. Ligand (L) binding
2. Receptor (R)-ligand (L) internalization
3. Uncoating
4. Segregation of R and L
5. L delivery to lysossomes
6. L degradation
7. Reactivation of R
8. Recycling of R to cell surface
9. Formation of new coated pits
Targeting Liver ASGP Receptors
Previous studies
Target ASGP-R: attach galactosyl target residues to a 
carrier  containing efficient reporter groups
reporter - carrier – vector              - technique              - reference
- 111In – DOTA - gal                                          Gamma Imaging     Meade, et.al., 2003
- 99mTc - DTPA- GSA 
(galactosylated HSA)                                       SPECT               Vera et. al., 2001
- MION - ASF (asialofetuin)                                MRI              Brady, Weissleder, et al., 1993
- USPIO – AG (arabinogalactan)                        MRI              Brady, Weissleder, et. al., 1991
- SL (spin label)n – AG                                        MRI                  Gallez, et. al., 1994
- (GdDTPA)858gal2284- PL 
(polylysine – 2136 amino groups) MRI                Vera, et. al., 1995
- SPECT quantification of asialoglycoprotein receptor (ASGP-R)
correlated with hepatic function in normal vs. pathology
- Tumours (eg. hepatoma) have reduced ASGP-R, uptake of 
targeted drugs much decreased vs. normal 
- ASGP-R present in hepatic carcinoma metastases
- Some of these findings also detected by MRI
Our approach:
- Galactosyl residues were employed as a targeting device as 
part of dendrimeric glycoconjugates where they were 
attached to reporter groups containing the Ln(III)-binding
moiety, because galactose binding ASGP-R are exposed on 
the surface of liver parenchimal cells (~500,000/cell)
Targeting Liver ASGP Receptors
Previous results and our approach
DTPA- derived dendrimeric glycoconjugates
Synthetic Approach
Convergent synthesis
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Pro-chelator: DTPA bisanhydride
Sugar block: carboxylate functionalized
glycodendromer (G0, G1, G2)
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Synthesis of DTPA-bisamide glycoconjugates
Boc protected
HMD-functionalized
monovalent thioglycosides
Boc protected
HMD-
functionalized
divalent
thioglycosides
and deprotection
TFA-DCM 
TFA-DCM 
TFA-DCM 
i) DIPEA/DCM
ii) DCC/HBT, DCM
DCC/HBT, DCM
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a- R1= OH and R2= H - DTPA(Gal)2
b- R1= H and R2= OH - DTPA(Glc)2
c- R1=H and R2= β−D-galactopyranosyl - DTPA(Lac)2
2 - DTPA(Gal)4
a, b
a,b 1
Synthesis of DTPA-bisamide glycoconjugates
DTPA-bisamide glycoconjugates: mono and divalent dendromers
a) i) DIPEA/DCM; ii) DMF
b) i) KOMe/EtOH;  ii) Amberlist 15, NH3(aq)
iii) RPC8 silica, elution with H2O/MeOH
NMR characterization of Ln-DTPA-bisamides
chelates
L = DTPAGal2
LaL 25 ºC
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Coordination polyhedrons of the
eight enantiomers of
Ln-DTPA-bisamides chelates
Conformational interconversion in
the diethylenetriamine backbone of
Ln-DTPA-bisamides chelates
Geraldes et al, Inorg. Chem., 1993
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Freed Theory of Outer-Sphere Proton Relaxivity
Outer-sphere term – parameters: aGdH, DGdH,  ∆2,  τv
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Free diffusion model
NMRD of Gd-DTPA - glycoconjugate
25 ºC
60 ºC
Gd(III)DTPALac2
Parameters from the analysis of the NMRD profiles
Gd(III)-DTPA-glycoconjugates
kex298/ 106 s-1 3.3±0.2 0.45±0.1 0.40
∆H‡ / kJ mol-1 51.6±1.4 47.6±1.4 40.0
τrH298 / ps 58±11 66±11 332±10
ERH / kJ mol-1 17.3±0.8 21.9±0.5 36.3±0.2
τv298 / ps 25±1 25±1 10±2
Ev / kJ mol-1[g] 1.6±1.8 3.9±1.4 1
∆2 / 1020 s-2 0.46±0.02 0.41±0.02 0.63±0.02
DGdH298/ 10-10 m2 s-1 20±3 23±2 24.0
DTPA DTPA-BMA DTPALac2
EDGdH /kJ mol-1 19.4±1.8 12.9±2.1 20
green parameters are fixed in the fit; Gd-DTPA-BENGALAA: τrH298 = 265 ± 22 ps, Lammers, et al, 1997)
Gamma Scintigraphy of Wistar rats
153Sm(III) labeled glycoconjugates
DOTAGal2 30 min DOTAGlc2 30 min
- Gal conjugates target liver
Gal < Gal2 ~ Gal4 
- Lac conjugates intermediate
- Glc conjugates do not
Uptakes as % ID are small
Biodistribution in Wistar rats
153Sm(III)-glycoconjugates
- Gal conjugates target liver
Gal < Gal2 < Gal4 
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- A series of new  DTPA glycosidase-resistant dendrimeric
glycoconjugates was synthesized and chemically characterized
- The solution structure of some of their Ln complexes was studied by NMR
- The water relaxivity of their Gd(III) chelates was investigated by NMRD
- Preliminary studies of the pharmacokinetics and biodistribution of the
153Sm-labeled glycoconjugates in Wistar rats shows selective liver uptake of
the glycoconjugates with galactose terminal groups but not  of the others
- These new glycoconjugate ligands may be selective to the liver ASGPR
and are potentially useful for liver targeting and imaging ( 153Sm3+, 111In3+ for
gamma scintigraphy and Gd(III) for MRI)
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